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Meeting AHA/ACC secondary prevention goals
in a vascular surgery practice: An opportunity we
cannot afford to miss
Daniel Kinikini, MD, Mark R. Sarfati, MD, Michelle T. Mueller, MD, and Larry W. Kraiss, MD,
Salt Lake City, Utah
Objective: In an effort to reduce cardiovascular mortality, patients with atherosclerotic arterial disease should undergo
risk factor modification according to the American Heart Association/American College of Cardiology (AHA/ACC)
Secondary Prevention Guidelines (hereafter, Guideline). We assessed compliance with the Guideline in a group of
patients seen in a vascular surgery practice.
Methods: We evaluated 200 consecutive patients with lower-extremity occlusive disease, cerebrovascular disease, or
abdominal aortic aneurysm seen by a university-based vascular surgery practice. The subjects were patients who had been
seen previously in our clinic (ESTABLISHED) and new referrals (NEW). Data pertinent to each of the nine AHA/ACC
Guideline goals were collected from patient interviews, medication histories, and laboratory records. Compliance with
each of the Guideline goals was evaluated. Differences in compliance between ESTABLISHED and NEW patient groups
were also compared. We also recorded whether a patient had a previous endovascular or open surgical vascular
intervention (EVENT or NO EVENT). Differences in compliance between the EVENT and NO EVENT groups were
compared.
Results: Most patients did not achieve the secondary prevention goals recommended in the Guideline. Patients who had
a prior vascular intervention (EVENT) were significantly more likely to achieve goals for low-density lipoprotein level
(43% vs 23%), and for statin (71% vs 39%), -blocker (46% vs 27%), angiotensin-converting enzyme inhibitor (53% vs.
35%), and antiplatelet agent (85% vs. 68%) use (P < .05). ESTABLISHED patients were significantly more likely than
NEW patients to have a prior EVENT (87% vs 47%, P < .0005). ESTABLISHED patients were significantly more likely
thanNEWpatients to achieve goals for low-density lipoprotein level, -blocker, and statin use; however, these differences
were likely due to the higher proportion of EVENT patients in the ESTABLISHED group.
Conclusion: Compliance with the Guideline is suboptimal in patients with atherosclerotic arterial disease. Secondary
prevention goals were more often achieved in the EVENT patient group, suggesting that a vascular intervention may lead
to increased patient and physician awareness and compliance with the Guideline. A targeted effort towards risk factor
modification in patients with atherosclerotic arterial disease could improve compliance with the Guideline and reduce
cardiovascular mortality. ( J Vasc Surg 2006;43:781-7.)Atherosclerosis is a systemic disease with many clinical
manifestations. A large portion of most vascular surgery
practices consists of patients with peripheral arterial occlu-
sive disease (PAD), cerebrovascular disease (CVD), and
abdominal aortic aneurysms (AAAs). The first two disor-
ders are direct manifestations of atherosclerotic disease, and
the third is strongly associated with atherosclerosis,1-3 All
of these patients have a high prevalence of coronary
artery disease (CAD).4-8 Patients with peripheral vascu-
lar disease have a shortened lifespan, primarily because of
premature death from ischemic heart disease.4,9,10 Pa-
tients with severe symptomatic PAD are up to 15 times
more likely to die from a cardiovascular cause than
healthy, age-matched controls.10
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doi:10.1016/j.jvs.2005.12.002Efforts have been made to identify interventions that
can reduce morbidity and mortality in patients at high
risk for cardiovascular related diseases. Numerous trials
have produced level I evidence that antiplatelet drugs,11,12
angiotensin-converting enzyme (ACE) inhibitors,13 3-hydroxy-
3-methylgluatryl coenzyme A (HMG CoA) reductase in-
hibitors (statins)14 and -blockers15 can reduce cardiovas-
cular mortality. Based on these studies, the AmericanHeart
Association (AHA) and the American College of Cardiol-
ogy (ACC) have published guidelines for the secondary
prevention of myocardial infarction and cardiovascular
death.16 PAD, CVD, and aortic aneurysmal disease have
been termed CAD equivalents because of their high asso-
ciation with CAD.17 Patients with these diagnoses are at
similar risk for cardiovascular-related death as those with
documented CAD. The AHA, ACC, and the Joint Brit-
ish Societies’ cardiovascular disease guidelines have rec-
ommended that patients with these diagnoses undergo
medical intervention in accordance with secondary pre-
vention guidelines.16,18 Despite these recommenda-
tions, patients with PAD and other noncoronary athero-
sclerotic diseases are often underprescribed protective
medications.19,20
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based vascular surgery practice to assess compliance with
consensus guideline recommendations. Our primary hy-
pothesis was that patients in a vascular surgery practice are
undertreated with respect to risk factor management as
recommended in the AHA/ACC Secondary Prevention
Guideline (hereafter referred to as the Guideline). A second
hypothesis was that patients who see a vascular specialist
will have improved compliance with the Guideline.
METHODS
The study was a prospective survey of 200 patients with
atherosclerotic arterial disease who were seen in the Uni-
versity of Utah Vascular Surgery clinic and was approved by
the University of Utah Institutional Review Board.
Three major diagnostic groups were included:
● Peripheral arterial diseasewas defined by a prior lower-
extremity revascularization or a clinical diagnosis of
claudication, ischemic rest pain, or tissue loss in con-
junction with an abnormal peripheral pulse examina-
tion and an ankle-brachial index 0.9.
● Abdominal aortic aneurysm was defined as the pres-
ence of an AAA 3 cm in diameter, confirmed by
radiographic or operative evaluation, or both. Patients
with aneurysms that had previously been repaired
and those who were undergoing surveillance were
included.
● Cerebrovascular disease was defined as a history of
carotid endarterectomy or an abnormal result on a
carotid duplex scan (internal carotid artery peak sys-
tolic velocity125 cm/s), with or without a history of
hemispheric stroke, transient ischemic attack, or am-
aurosis fugax.
All vascular diagnoses were confirmed by an attending
vascular surgeon. We also determined which patients had a
clinical diagnosis of CAD based on a history of myocardial
infarction, angina, percutaneous coronary intervention, or
coronary artery bypass graft surgery. These data were ob-
tained by patient interview and review of that patient’s
medical records.
To evaluate the influence of care by a vascular surgeon,
we obtained data on two separate groups of patients: those
seen in clinic for the first time (NEW group) and those who
had been seen on at least one previous occasion by a clinic
vascular surgeon (ESTABLISHED group). Although the
participating vascular surgeons were aware of the Guidelines,
there was no specific intervention plan or protocol to institute
indicated therapies in the NEW or ESTABLISHED patients.
The study was designed as an initial audit to evaluate
current compliance with the Guidelines. Data on whether
new medications were prescribed or other medical inter-
ventions recommended during the clinic visit were not
collected.
Data were collected over a consecutive 10-week period.
NEW and ESTABLISHED patients were accrued concur-
rently. Our intent was to enroll 100 NEW patients and 100
ESTABLISHED patients. Although we attempted to en-roll all patients with arterial disease seen in clinic during the
10-week audit period, no mechanism was in place to iden-
tify missed patients. Data were prospectively collected by
using a physician-completed data sheet. Supplementary
information was also obtained from referring physician
records when necessary.
Data pertinent to each of the nine AHA/ACC guide-
lines as well as for statin use were collected (Table I).
Although the Guideline does not specifically list statin use
as one of the defined goals, it is listed as a first-line therapy
in cholesterol reduction. Also, because many of the bene-
ficial effects of statins seem to be independent of cholesterol
lowering21-23 and may have specific benefits in patients
with PAD,24,25 we obtained data on statin use in our
population.
The Guideline recommends -blockers in all patients
with a history of myocardial infarction or acute coronary
syndrome and as indicated for the management of hyper-
tension, arrhythmia, and angina. -Blockers are also
indicated in many patients undergoing major vascular
operations. Given the broad indications for -blocker use
in patients with vascular disease, we thought it was appro-
priate to specifically analyze -blocker use in all of our
patients.
Blood pressure, height, and weight were recorded dur-
ing the clinic visit. Blood pressure was assessed by a single
measurement obtained during the clinic visit. Smoking
history and exercise patterns were obtained by patient
interview. Medication use was obtained by patient inter-
view and, if necessary, query of the primary care physician.
Laboratory data for lipid levels and HbA1c were obtained
from the electronic medical record if the patient was re-
ferred from within the university system, or from the pa-
tient’s laboratory record obtained from the referring phy-
sician’s office. An unavailable laboratory value was defined
as being either entirely absent from the patient’s medical
Table I. American Heart Association/American College
of Cardiology Guidelines for Secondary Prevention16
Intervention point Guideline goal
Smoking Complete cessation
Blood pressure control 140/90 mm Hg; 130/80
in diabetic patients
Lipid management/statin use LDL cholesterol 100 mg/dL
Physical activity 30 min, 3 times/week
Weight management BMI 25
Diabetes management HbA1c 7%
Antiplatelet/anticoagulant use Use in all if not contraindicated
ACE inhibitor use Use in all post-MI, consider in
all others
-Blocker use Use in all post-MI, in others as
indicated for hypertension,
arrhythmia, and angina
LDL, low-density lipoprotein; BMI, body mass index; ACE, angiotensin-
converting enzyme; MI, myocardial infarction.record (never checked), or by values that were older than 1
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chosen because both the American Diabetes Association
and the National Cholesterol Education Panel recommend
checking HbA1c and low-density lipoprotein (LDL) cho-
lesterol levels at least every 6 months.17,26 Unavailable
laboratory data were listed as not meeting the Guideline
recommendation.
To evaluate the influence of medical specialty on com-
pliance, we recorded the specialty type of each referring
physician. To evaluate the possibility of a “system effect,”
we recorded whether the referring physician was a part of
the same university health-care system as the vascular sur-
gery clinic.
To evaluate the possible effect that a specific opera-
tive or procedural intervention may have on a patient’s
compliance to guideline therapies, we collected data
on whether such an intervention had occurred before
the date of the patient interview. Such an occurrence
was termed an EVENT and defined as a therapeutic
coronary or peripheral intervention, AAA repair, or ca-
rotid intervention (either open or percutaneous).
We asked whether Guideline compliance correlated
with the length of time a patient was enrolled in the vascular
clinic. For the ESTABLISHED group, we recorded time
(in months) that patients had been seen and treated by
clinic physicians. Descriptive statistics were used to show
overall compliance rates to each individual Guideline goal
and to evaluate the total number of goals met for each
individual patient. Differences in compliance with individ-
ual Guideline goals between the NEW and ESTAB-
LISHED groups were compared by using the 2 test. The
Student’s t test was used to compare the mean number of
goals met per patient between NEW and ESTABLISHED
groups as well as between patients with and without CAD.
All computations were performed by using Stata-8.0 statis-
tical software (StataCorp, College Station, Texas). Statisti-
Table II. Demographics
Characteristic
Total
(n  200)
ESTABLISHED
(n  100)
NEW
(n  100) P
Age
(mean  SD) 68.8  10 68.4  10 69.1  11 .678
Male, n (%) 139 (70) 71 (71) 68 (68) .645
Female, n (%) 61 (30) 29 (29) 32 (32)
Known CAD
n (%) 78 (39) 35 (35) 43 (43) .246
Previous MI,
n (%) 60 (30) 32 (32) 28 (28) .537
Diabetes, n (%) 59 (30) 32 (32) 27 (27) .438
PAD, n (%) 100 (50) 53 (53) 47 (47) .543
CVD, n (%) 52 (26) 21 (21) 31 (31) .085
AAA, n (%) 48 (24) 28 (28) 20 (20) .112
CAD, Coronary artery disease; MI, myocardial infarction; PAD, peripheral
arterial disease; CVD, cerebrovascular disease; AAA, abdominal aortic
aneurysm.cal significance was assumed if P  .05.RESULTS
During a 10-week period, one hundred NEW patients
and 100 ESTABLISHED patients were surveyed, of whom
70%weremen and 30%women. Their average age was 68.8
years. The primary diagnosis was PAD in 50%, AAA in 24%,
and CVD in 26%. CAD had been diagnosed in 39%, and
30% had diabetes mellitus. The NEW and ESTABLISHED
groups did not differ significantly in age, sex, history of
coronary artery disease, prior myocardial infarction, diabe-
tes mellitus, or primary vascular diagnosis (Table II).
Compliance rates were noted for each of the nine
Guideline goals as well as for statin use (Figs 1 and 2).
Overall, 73% were current nonsmokers, of whom 66% were
former smokers. Fifty-four percent met the Guideline goal
for blood pressure. Only 36% were compliant with Guide-
line recommendations for LDL cholesterol level. Thirty-
five percent reported regular exercise according to goal
standards, and 33% had a body mass index at goal levels. Of
the patients with diabetes mellitus, 24% were compliant
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Fig 1. Guideline compliance. *Reflects diabetic population only;
14 (24%) of 59 patients with diabetes had HbA1c levels 7%. BP,
Blood pressure; LDL, low-density lipoprotein; BMI, body mass
index.
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Fig 2. Guideline medication use. ACE, angiotensin-converting
enzyme.with Guideline goals for HbA1c levels.
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patients were taking a statin drug, and 79% were taking an
antiplatelet agent or warfarin. Forty-eight percent were
taking an ACE inhibitor, and 40% were taking a -blocker
(Fig 2).
A significant number of patients had unavailable data
for the twoGuideline goals requiring laboratory assessment
of LDL andHbA1c. LDL levels were unavailable for 38% of
patients, and HbA1c levels were unavailable for 39% of
diabetic patients. Unavailable laboratory data were listed as
not meeting the Guideline recommendation.
Patients with a known diagnosis of CAD met an aver-
age of 5.3 goals per patient compared with 4.6 goals per
patient in those without known CAD (P  .0004). There
was no difference in the number of goals met in diabetic vs
nondiabetic patients (Table III).
Only one of 200 patients met every Guideline goal. The
mean number of Guideline goals met was 4.8  1.5 (SD)
(Fig 3). When the two groups were compared, we noted
significantly higher compliance in the ESTABLISHED
group in three areas (Fig 4). LDL cholesterol was at Guide-
line goal (100 mg/dL) in 45% of ESTABLISHED pa-
tients vs 27% of NEW patients (P  .027). In accordance
with this, the ESTABLISHED group was found to bemore
likely to be taking a statin medication than the NEW group
(70% vs 51%, P  .006). -Blocker use was also more
frequent in ESTABLISHED patients (47% vs 32%, P .03).
A trend toward increased antiplatelet use was found in
ESTABLISHED patients, but statistical significance was
not reached (P  .083). The ESTABLISHED group met
an average of 5.1 goals per patient compared with 4.6 goals
Table III. Number of Guideline goals met per patient
Group
Number goals
met per pt  SD P
Total 4.8  1.5 NA
ESTABLISHED 5.1  1.5 .028
NEW 4.6  1.6
CAD 5.3  1.5 .0004
No CAD 4.5  1.5
Diabetes 5.0  1.5 .261
No diabetes 4.8  1.6
NA, not applicable; CAD, coronary artery disease.
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Fig 3. Number of Guideline goals met.per patient in the NEW group (P  .028).ESTABLISHED patients were nearly twice as likely to
have had an EVENT before the survey than NEW patients
(87% vs 47%, P  .0005). Those patients who had experi-
enced an EVENT before the survey were more likely to be
compliant with five of the 10 Guideline goals (Table IV).
Patients with prior EVENTS were more often compliant
with LDL levels and were more likely to be taking a statin,
ACE inhibitor, -blocker, and an antiplatelet agent.
ESTABLISHED patients had been seen by the clinic
physicians for a median time of 16 months (interquartile
range, 6 to 29 months). The only difference in compliance
to Guidelines seen in patients seen for greater than the
16-month median time compared with those seen for less
time was in -blocker use. Increased -blocker use was seen
in those patients in clinic for 16 months (58% vs 35%,
P  .026).
Most patients (91%) were referred by internal medicine
or family practice physicians. Cardiologists referred 9% of
patients. Thirty percent of referring physicians were a part
of the same university health-care system as the vascular
surgery clinic. Patients referred by cardiologists were more
likely to use -blockers (82% vs 36%, P  .005) and more
likely to be current nonsmokers (94% vs 72%, P  .047)
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Fig 4. Compliance differences between NEW and ESTABLISHED.
LDL, low-density lipoprotein.
Table IV. Guideline compliance by EVENT
vs NO EVENT
EVENT
(n133) (%)
NO EVENT
(n  67) (%) P
Statin use 71 39 .0005
LDL 100 mg/dL 43 23 .019
-Blocker use 46 27 .012
ACE use 53 35 .014
Antiplatelet use 85 68 .006
Exercise 35 36 .805
Nonsmoker 76 68 .244
BP 140 mg Hg 53 56 .648
BMI 25 34 32 .776
Hgb A1C 7 25 20 .405
EVENT, Coronary or peripheral intervention (percutaneous or open), or
abdominal aortic aneurysm repair or carotid endarterectomy; LDL, low-
density lipoprotein; ACE, angiotensin-converting enzyme.than patients referred by primary care physicians. No dif-
systoli
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patients referred by physicians within the university health-
care system were compared with those referred by physi-
cians outside the system.
DISCUSSION
Patients seen by vascular surgeons for arterial disease
carry a heavy atherosclerotic burden. The co-prevalence of
CAD with other forms of atherosclerotic disease is very
high.7,8 When cohorts of patients with PAD, CVD, or AAA
are followed, they invariably show a markedly increased
mortality—predominately because of ischemic heart dis-
ease.4,9,10,27 These groups have been identified by the
AHA/ACC and the Joint British Societies as groups that
should receive targeted secondary prevention interven-
tions.16,18 Level I evidence from clinical trials has shown
improved patient survival with the use of statins,14 ACE
inhibitors,13 antiplatelet agents,11,12 and -blockers.15,28
This evidence provided the impetus for the AHA/ACC
Secondary Prevention Guidelines.
The Guideline reflects the findings of large, prospec-
tive, randomized trials and may be considered the best
available medical therapy for the prevention of myocardial
infarction and cardiovascular death in patients at high risk.
We therefore chose the Guideline as the benchmark to
measure the adequacy of secondary prevention measures in
our patients. Although the Guideline does not specifically
list statin use as one of the defined goals, it is listed as a
first-line therapy in cholesterol reduction. Also, because of
the beneficial effects of statins seem to be independent of
cholesterol lowering21-23 and may have specific benefits in
patients with PAD,24,25 we obtained data on statin use in
our population.
We found that patient compliance with the Guideline
in our vascular surgery clinic is suboptimal but consistent
with previous reports (Table V).29-34 The mean number of
Guideline goals met per patient was 4.8. Only one patient
of 200 was compliant with all recommendations. Most
patients were compliant with five or less of the recom-
mended goals. Patients with a known diagnosis of CAD
met more Guideline goals than those without CAD. A
diagnosis of CAD likely alerts the primary care physician to
the need for risk factor management. Improved risk factor
management has been noted in patients with known CAD
in other studies as well.20,35 We examined the influence of
Table V. Comparisons with similar studies
Study -Blocker
ACE
Inhibitor Stat
Current study (n  200) (%) 40 48% 61
Rehring, et al34 (n  1733) (%) 33 29 31
Henke, et al33 (n  293) (%) 69 54 56
Ness, et al32 (n  1006) (%) 60 62 67
ACE, angiotensin-converting enzyme; LDL, low-density lipoprotein; SBP,
*Includes statins and other anti-lipid agents.primary care provider type on compliance. There was noapparent difference in compliance between patients re-
ferred by university physicians vs community-based provid-
ers. Patients referred by cardiologists were more likely to be
taking a -blocker and to be nonsmokers.
ESTABLISHED patients met more Guideline goals
per patient than NEW patients. One of our initial hypoth-
eses was that patients who see a vascular specialist would
have improved compliance with guideline recommenda-
tions. The finding of improved compliance in some areas
seen in ESTABLISHED patients seemingly validated this
hypothesis.When evaluatedmore closely, however, we found
that the strongest factor associated with improved compliance
was whether or not a patient had a surgical or percutaneous
vascular intervention (EVENT). ESTABLISHED patients
were significantlymore likely to have had anEVENT, and this
association is likely the cause of any improved compliance seen
in the ESTABLISHED group compared with the NEW
group. Length of time as a patient in vascular clinic did not
correlate with improved compliance.
These findings do not negate the role or influence of
the vascular surgeon in improving risk factor management
in patients with atherosclerotic vascular disease. The data
show a clear need for improvement and an opportunity to
improve guideline compliance in patients seen in a typical
vascular surgery clinic. The data also suggest that an
EVENTmay be an opportunity to influence the behavior of
both patients and physicians when it comes to compliance
with guideline goals. Vascular surgeons are often the ones
who administer the EVENT to the patient and therefore
are uniquely positioned to capitalize on this “teachable
moment.”
Despite compelling evidence from numerous clinical
trials and strong recommendations from the AHA, ACC,
and the British cardiovascular societies, this and other
studies have shown that patients with peripheral vascular
disease receive less intensive management of their cardio-
vascular risk factors than patients with CAD.19,33-37 This
observation has several possible explanations. Peripheral
vascular disease is often unrecognized by the patient and
the primary care physician. The Peripheral Arterial Disease
Awareness, Risk and Treatment, New Resources for Sur-
vival (PARTNERS) investigators screened patients in 350
primary care practices for the presence of PAD.20 About
one-third of the patients had evidence of PAD, but only
one-half of those had previously been diagnosed. Even in
Aspirin/
anti-coagulation
LDL
100 mg/dL
HgbA1c
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79% 36% 24% 54%
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patients. Primary care physicians may be unaware of the
association between PAD and CAD. A significant number
of patients with PAD may not have symptoms related to
their CAD. Physicians may be unaware that the Guidelines
for Secondary Prevention should be applied to patients
with PAD even if they have no overt symptoms of CAD.
Although the goal of secondary prevention is the re-
duction in myocardial infarction and cardiovascular death,
many of the interventions may also yield other benefits
specific to vascular surgery patients. This “two-for-one”
concept can be postulated for many of the Guideline goals.
The behavior modification goals of smoking cessation and
exercise are examples. These are the same behavioral adjust-
ments that are of importance in the nonoperative manage-
ment of claudication and have been shown to yield in-
creased walking distance in randomized trials.38 Smoking
cessation is likely to decrease the need for limb salvage
revascularization.39 There is also evidence of improved
graft patency and limb salvage when statins are used.25
Statins have also been shown to have a suppressive effect on
matrix metalloproteinase-9 in AAA wall.40
Diabetic patients have an increased risk of PAD and a
higher risk of critical limb ischemia and amputation.41
High-intensity control of diabetes has been shown in a
randomized trial to reduce the rates of amputation and the
need for revascularizaton.42 A recently published meta-
analysis also confirmed significantly improved graft patency
rates with antiplatelet use.11 In addition to reducing long-
termmortality, -blockers and statins have also been found
to reduce perioperative mortality following noncardiac vas-
cular surgery.25,43,44
Previous studies evaluating risk factor management in
vascular surgery patients have been retrospective in nature
and have evaluated patients mainly with PAD.29,33,37 Our
study is unique in several respects:
First, it is a prospective survey of patients with a variety
of atherosclerotic arterial disease diagnoses. This study
population is likely to be representative of most vascular
surgery practices.
Second, we used the AHA/ACC guidelines as a bench-
mark and calculated compliance with each of the nine
specific guideline goals as well as statin use.
Third, data collection was via direct patient interviews;
and diagnoses were confirmed by vascular surgeons. These
direct methods may yield more robust data than previous
studies that have used computerized pharmacy databases,
surveys, and diagnostic or procedure codes to establish
compliance rates and diagnoses.34,36
The results of this study should therefore be more
reflective of the current state of atherosclerotic risk factor
management in a typical vascular surgery practice.
The limitations of this study include a small study
population, a one-time “snap-shot” view of our clinic pop-
ulation’s compliance with the Guidelines, and the inability
to establish a causal relationship between improved com-
pliance in the ESTABLISHED group and the influence of
a vascular surgeon. The study population size of 200 wasarbitrarily chosen as a manageable group to survey because
the major goal was to perform a quality control audit of this
group’s compliance with Guideline goals. The audit has
served its purpose by exposing suboptimal secondary pre-
ventative treatment.
The study is also encouraging in that it has defined an
opportunity to improve compliance with Guideline goals.
The next phase is to develop and implement a plan that will
result in improved guideline compliance in our patients.
The data collection was a one-time “snap shot” of compli-
ance and is therefore subject to sampling errors. The pri-
mary method of data collection was a physician interview of
the patient. Although we recognize that this may be subject
to inaccuracies, the interviewer tried to clarify any discrep-
ancies by reviewing the electronic medical record and con-
tacting the primary care provider.
The assessment of blood pressure control was based
largely on the measurements obtained during the clinic
visit. We recognize that inaccuracy of a single measurement
and did try to confirm a pattern of poor control during the
interview.
CONCLUSION
Many of the patients seen in vascular surgery clinics are
referred when atherosclerotic vascular disease is discovered
or suspected but does not yet require intervention. This
initial clinic visit, however, is a strategic opportunity for the
surgeon to discuss the systemic nature of atherosclerosis
with the patient and to ensure that the patient is undergo-
ing appropriate atherosclerotic risk factor management.
Vascular surgeons should be familiar with the AHC/ACC
Secondary Prevention Guidelines, and the literature they
are based on, to remain leaders in the evolving world of
vascular medicine. We suspect that most vascular surgery
patients are undertreated with respect to risk factor modi-
fication guidelines and that a great opportunity for inter-
vention exists.
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